Thank you to our volunteers 1st - 7th of June is National Volunteers Week and we want to say thank you! In 2022/23 the team here at Action …
Fighting for the future
Fighting for the future While we continue our much needed day to day work supporting our families, I want to share with you the recent developments …
Join us for the second half of Yes I Can Online
Join us for the second half of Yes I Can Online We are now half way through our 12 online sessions. So far we've heard from Alex James and …
Isaac White tells us all about his first fundraising event for Action Duchenne
Isaac White tells us all about his first fundraising event for Action Duchenne "Party Planning is what I was born to do! Enjoy!" On Friday …
Isaac White tells us all about his first fundraising event for Action DuchenneRead More
Ask the pharmaceutical companies your questions ahead of Action Duchenne’s 2023 Annual International Conference
Ask the pharmaceutical companies your questions ahead of Action Duchenne's 2023 Annual International Conference To make sure you get your voice …
Roche UK issues statement to the Duchenne Community following Sarepta’s Update on Regulatory Review of SRP-9001 gene therapy.
Roche UK issues statement to the Duchenne Community following Sarepta's Update on Regulatory Review of SRP-9001 gene therapy. Following the update …
Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001
Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001 Sarepta Therapeutics, today provided the following update on the Biologics …
Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001Read More
PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy
PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne …
Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular …
The story behind Ruth’s charity dinner dance
The story behind Ruth's charity dinner dance Ruth and Ian Taylor tell us about their journey with Duchenne so far in this inspiring interview. Ruth …
Take part in our Turning Point survey for a chance to win a £20 Amazon Voucher!
We need you! Are you a parent/caregiver of a child living with Duchenne? Are you a teacher, TA, SENDCO or clinician working with someone living …
Take part in our Turning Point survey for a chance to win a £20 Amazon Voucher!Read More
Vamorolone NDA mid-cycle review meeting by FDA completed
Vamorolone NDA mid-cycle review meeting by FDA completed Santhera Pharmaceuticals and ReveraGen BioPharma, Inc announce the successful completion …
Vamorolone NDA mid-cycle review meeting by FDA completedRead More
